Animal health company Zoetis Inc. (ZTS) is closing out 2025 with a wave of regulatory progress that could reshape its product portfolio across companion animal and livestock care. Recent approvals and positive opinions from global health authorities indicate the company's continued commitment to long-acting monoclonal antibody therapies for osteoarthritis pain, an area of growing clinical and commercial significance.
With updated financial guidance and multiple launches expected in 2026, Zoetis is positioning itself for sustained performance in the year ahead.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.